We’ve
been focusing on changing therapies in the hemophilia community the past two
years, including products that give us more options and choices. Read below to
learn about how Biogen scientists developed two products that are being used to
help improve hemophilia care.

Please see below for the Indications
and Important Safety Information

In
2000, Rob Peters and Jenny Dumont, currently top scientists at Biogen, wanted
to make a difference in hemophilia care. They saw that hemophilia therapy
hadn’t changed since the 1970s and there was an unmet need for a
new class of treatment.

Rob,
Jenny, and their team knew it wouldn’t be easy. They were fully aware that it
often takes years, even decades, to get a therapy from that spark of
inspiration through research, clinical trials, and FDA approval to the
community who so eagerly wanted an alternative therapy.

Rob
has a PhD in biochemistry from Harvard and is a VP, Hematology Research, at
Biogen. Jenny has her PhD in cell biology from the University of Cincinnati
College of Medicine and is the Medical/Scientific Director, Global Medical, at
Biogen. Both certainly had the education and training to tackle such a daunting
challenge. More importantly, Rob and Jenny had an unwavering passion to develop
new therapies.

Their
passion helped them stick with it and in 2014, after a decade and a half of
hard work and determination, Biogen launched prolonged half-life ELOCTATE® [Antihemophilic
Factor (Recombinant), Fc Fusion Protein] and ALPROLIX®
 [Coagulation
Factor IX (Recombinant), Fc Fusion Protein].

Prolonged
half-life ELOCTATE and ALPROLIX have been helping people with hemophilia for
the past two years. In that time, doctors have written thousands of
prescriptions.

Rob
and Jenny recently returned from the National Hemophilia Foundation and World
Federation of Hemophilia meetings, where they had the opportunity to talk with
people who have been taking ELOCTATE and ALPROLIX. They got to see, firsthand,
that their perseverance and passion was well worth the effort.

“Bringing
ELOCTATE and ALPROLIX from inception to the people who need them was a lot like
raising children,” Jenny says. Jenny is a mother of 2 and grandmother of 3. “You
give them so much of your energy and attention for so many years, then let them
go into the world and hope they make an impact.”

Rob, father of eight-and-a-half-year-old twins, agrees, adding: “I was raising my twins the
same time we were developing ELOCTATE/ALPROLIX. That really helped me
appreciate the potential of what more time between infusions could mean in the
lives of families with kids with hemophilia.”

Learn
about the science behind ELOCTATE  and ALPROLIX .

ELOCTATE Indications

ELOCTATE
is an injectable medicine that is used to help control and prevent bleeding in
people with hemophilia A (congenital Factor VIII deficiency). Your healthcare
provider may give you ELOCTATE when you have surgery.

ELOCTATE Selected Important Safety
Information

Do
not use ELOCTATE if you have had an allergic reaction to it in the past.

Please
see ELOCTATE.com  for the Indications and Full Important Safety Information, as well
as the full Prescribing Information.

ALPROLIX Indications

ALPROLIX
is an injectable medicine that is used to help control and prevent bleeding in
people with hemophilia B. Hemophilia B is also called congenital Factor IX
deficiency.

Your
healthcare provider may give you ALPROLIX when you have surgery.

ALPROLIX Selected Important Safety
Information

Do
not use ALPROLIX if you are allergic to ALPROLIX or any of the other
ingredients in ALPROLIX.

Please
see ALPROLIX.com for the Indications and Full Important Safety Information, as well
as the full Prescribing Information.

This blog was sponsored by Biogen for
educational purposes.

HEM-US-1198
08/16

©2016
Biogen. All rights reserved.